National Institute for Medical Research
Mwanza, Tanzania
Location contact
Belinda Kweka, MD, MSc
CONTACT
George PrayGod, MD, PhD
CONTACT
NCT Number: NCT06781918
This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.
Researchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.
Participants will:
* Be given the trial interventions which will be delivered over 12 weeks * After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.
Trial opening soon.
Get Notified6 month–36 month
All sexes
Interventional
Phase 3
Mwanza, Tanzania
Belinda Kweka, MD, MSc
CONTACT
George PrayGod, MD, PhD
CONTACT
Background Estimated, 13.6 million children were affected by severe acute malnutrition (SAM) in 2022. Early childhood is a critical period of brain development and children exposed to malnutrition in early life have poorer school performance and lower income in adult life. Introduction of Ready to use therapeutic foods (RUTF) has greatly improved the nutritional recovery of children with SAM. However, SAM remains associated with adverse effects on child cognitive and social development. The balance in the RUTF between polyunsaturated n-6 and n-3 essential fatty acids (EFAs) in RUTF has been questioned. Essential fatty acid (EFA) status is associated with child development, and children given the standard RUTF do not improve their n-3 EFA status after recovery.
A trial in Malawi found a positive effect on cognitive scores six months after completing nutritional therapy with RUTF with added preformed docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid (PUFA) of the n-3 series, which is essential for neural growth. There is also a potential for improving the content of other nutrients of importance for neurodevelopment in early childhood like choline, which is essential for neurotransmitter synthesis and phospholipids in the brain. Studies have indicated a synergistic relationship between n-3 EFAs and choline, suggesting that low levels of one or both may negatively impact cognition.
Deficits in child development associated with SAM are not only caused by inadequate diets. Families exposed to malnutrition are often affected by psychological distress, consequently children are likely to be offered little stimulation and responsive care. However, in practice, support for psychosocial stimulation and responsive caregiving is rarely offered during hospital-based treatment, and it is still not included in the guidelines for community-based treatment of SAM. The intensity of this intervention is difficult under the constraints of most health services in low- and middle-income countries (LMIC). More recent packages for promoting responsive care have shown some effects, but often not when implemented at scale or within systems of care.
In this study we hypothesize that optimized nutritional treatment and integrated psychosocial support can improve the health and development outcomes of children with SAM.
Specific objectives:
Methods:
This trial is designed as a 2x2 factorial randomized clinical trial to assess the effects of DHA and choline enriched vs. standard RUTF and psychosocial stimulation vs. standard counselling in management of SAM. Participants will be individually randomised to nutritional intervention arms and clusters will be randomized to psychosocial intervention arms.
The interventions will be delivered over a period of 12 weeks. After enrolment and baseline data collection, participants will receive their first RUTF sachets. They will then be requested to return to the study site for a total of seven visits during the intervention period to receive interventions. After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks. The study will take place in Mwanza region, Tanzania. The trial will include children with uncomplicated SAM aged 6-36 months from eight health care facilities in Ilemela municipality, Nyamagana municipality and Magu district.
Outcomes:
The primary outcomes is the change in child development scores, which will be assessed at baseline, 12, 24 and 48 weeks and compared with intervention groups. These will assess gross, fine motor, language and psycho -emotional skills by validated tool called (MDAT) Malawi Development Assessment Tool) and neurocognitive function will be accessed by eye-tracking. Secondary outcomes will allow us to assess proximate effects of the interventions, which may mediate long-term effects on development
Analysis:
The primary analysis will be based on the intention-to-treat principle using available case data. The analysis will assess intervention effects based on the 2x2 factorial design by comparing changes in outcomes between baseline and intervention endline (i.e., 12 weeks) using a linear regression model adjusted for sex, age and month of inclusion to account for possible seasonal effects.
Secondary analysis will include assessment of intervention effects at 24- and 48-weeks follow-up using a linear mixed model to include repeated measurements. The models will include the baseline value of the outcome as fixed effect and participant as random effect to account for the correlation between measurements from the same participant. These models will also include adjustment for other variables as appropriate.
Secondary analyses will include per-protocol analyses to assess effects within groups with high compliance with the interventions
Ethics:
Ethical approval has been sought from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical Research in Tanzania and the London School of Hygiene and Tropical Medicine ethics committee.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DHA & Choline enriched RUTF The modified RUTF is a peanut butter paste that contains vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals the same nutrients which are the same as the standard RUTF but is fortified additionally with 250 mg of choline and 200 mg of preformed DHA per 92-gram sachet.
Standard RUTF The standard RUTF used in the BrightSAM trial is a peanut butter paste with vegetable oil, skim milk powder, carbohydrates, vitamins, and minerals that is intended to cover the child's total daily nutritional needs. Standard RUTF will be manufactured in compliance with the specifications recommended by the Codex Alimentarius Commission17.
The psychosocial intervention has been developed and piloted for this study as a context-relevant adaptation from the WHO/UNICEF Care for Child Development package. It will be delivered in group sessions, where the primary caregiver will attend along with the child participating in the trial.
During seven sessions of approximately two hours, caregivers will be trained on a variety of subjects which include; the first four sessions will be introductory and provide the basics of nutrition, the basics of psychosocial stimulation, and play and communication practices. We will build on the increasing experience of the caregivers and provide a deeper understanding of early child development.
Standard nutritional counseling will adhere to national guidelines for pediatric management of severe acute malnutrition including nutritional counseling and psychosocial stimulation.
Time frame: Assessed at baseline, 12, 24 and 48 weeks
Development will be assessed by validated methods and include:
Gross motor, fine motor, language, and psycho-emotional skills assessed by the Malawi Development assessment tool (MDAT)
Time frame: Baseline, 12, 24 and 48 weeks
Neurocognitive function assessed by eye-tracking technique
Time frame: Assessed at baseline, 12, 24 and 48 weeks
Caregiver stimulation and support assessed by Observations of Mother and Child Interactions (OMCI) questionnaire
Time frame: at baseline and at week 12, and week 48
Time frame: Baseline, weekly, 12, 24 and 48 weeks
Time frame: 12, 24 and 48 weeks
Proportion of children who die during follow-up
Time frame: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
The process evaluation will examine the following aspects of the interventions:
Time frame: Baseline, 12, 24 and 48 weeks
Levels of choline and related metabolites assessed by mass spectrometry
Time frame: Baseline, 12, 24 and 48 weeks
Serum CRP assessed as a marker of systemic inflammation
Time frame: Baseline, 12, 24 and 48 weeks
Serum ferritin assessed as marker of iron status
Time frame: Baseline, 12, 24 and 48 weeks
Serum alanine transaminase as a marker of liver function
Time frame: Baseline, 12, 24 and 48 weeks
Serum aspartate transaminase assessed as a marker of liver function
Time frame: Baseline, 12, 24 and 48 weeks
Maternal psychological distress assessed by Patient Health Questionnaire 9 (PHQ-9)
Time frame: Baseline, 12, 24 and 48 weeks
The status of learning environment assessed by the Family Care Indicators (FCI) questionnaire
Time frame: Baseline, 12, 24 and 48 weeks
The status of maternal social support framework assessed by the Multidimensional Scale of Perceived Social Support questionnaire
Time frame: 12, 24 and 48 weeks
. Proportion of children with one or multiple illness episodes during follow-up
Time frame: Baseline, 12, 24 and 48 weeks
Time frame: Baseline, 12, 24 and 48 weeks
Height-for-age z-score (HAZ) assessed based on length/height (m) and age (month)
Time frame: 12
Rate of nutritional recovery at the end of intervention period, defined as WHZ > -2 and MUAC > 125 mm, and no bilateral pitting oedema for two weeks
Time frame: 12 weeks
Proportion relapsing to moderate acute malnutrition (MAM) after recovery, measured as WHZ ≤ -2 and >-3 or MUAC ≤ 125 and >115mm)
Time frame: Any time point, 24 and 48 weeks
Proportion relapsing to SAM after recovery, measured as WHZ <-3, MUAC <115mm or presence of nutritional oedema, assessed at any caregiver-initiated contacts to the study site at any point during the 48 weeks of follow-up and at study visits at 24 and 48 weeks
Time frame: Interviews will be conducted after the last PS session ( Week 11) , and where possible, again with the same caregivers at long term follow-up (week 24 and 48).
The implementation component will assess
Contact information is provided by the study sponsor or research team.
Belinda Kweka, MD, MSc
CONTACT
George PrayGod, MD, PhD
CONTACT
National Institute for Medical Research, Tanzania
Other Gov
BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION
Acronym: BRIGHTSAM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07345884
Child Nutrition Disorders, Malnutrition, Child
Karachi, Pakistan
View Trial DetailsNCT06817421
Bacterial Infections, Bacterial Infections and Mycoses
Dili, Timor-Leste
View Trial DetailsNCT07026682
Acute Watery Diarrhea, Dehydration in Children
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT01889329
Severe Acute Malnutrition in Childhood
Dhaka, Bangladesh
View Trial Details